Physician profile
Daniel Johns
NPI 1376907782
$21,680.58
in general payments reported to CMS, 2019-2025
23 companies · $364 in 2025
The $364 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20K · 2021: $186 · 2022: $225 · 2023: $300 · 2024: $460 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $20,691.47 | 2020-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Abbott Laboratories | $144.30 | 2024 | Eterna |
| Relievant Medsystems, INC. | $125.65 | 2022-2023 | Intracept |
| Nevro Corp. | $117.65 | 2021-2024 | Senza |
| Medtronic, INC. | $96.17 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Abbvie INC. | $63.51 | 2021-2023 | |
| Globus Medical, INC. | $52.89 | 2025 | Senza |
| Biodelivery Sciences International, INC. | $43.07 | 2021 | |
| Redhill Biopharma INC. | $41.53 | 2021 | |
| Ibsa Pharma INC. | $35.69 | 2021 | |
| Alexion Pharmaceuticals, INC. | $35.07 | 2023 | Ultomiris |
| Lilly USA, LLC | $29.21 | 2022-2023 | Amyvid |
| Otsuka America Pharmaceutical, INC. | $25.52 | 2023 | Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $25.00 | 2023 | Gammagard |
| Biogen, INC. | $24.45 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $20.19 | 2022 | |
| Masimo Corporation | $18.43 | 2025 | Set and Rainbow Set |
| Spr Therapeutics, INC | $17.49 | 2025 | Sprint Pns System |
| Teva Pharmaceuticals USA, INC. | $16.80 | 2023 | Austedo |
| Jazz Pharmaceuticals INC. | $15.41 | 2023 | |
| Averitas Pharma INC. | $13.99 | 2023 | Qutenza |
| Cala Health, INC. | $13.57 | 2022 | |
| Saluda Medical Americas, INC. | $13.52 | 2025 | Evoke |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Johns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.